BG103686A - Тиазолови бензенсулфонамиди като бета3 агонисти за лечението на диабет и затлъстяване - Google Patents
Тиазолови бензенсулфонамиди като бета3 агонисти за лечението на диабет и затлъстяване Download PDFInfo
- Publication number
- BG103686A BG103686A BG103686A BG10368699A BG103686A BG 103686 A BG103686 A BG 103686A BG 103686 A BG103686 A BG 103686A BG 10368699 A BG10368699 A BG 10368699A BG 103686 A BG103686 A BG 103686A
- Authority
- BG
- Bulgaria
- Prior art keywords
- ethyl
- phenyl
- hydroxy
- benzenesulfonamide
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3676097P | 1997-01-28 | 1997-01-28 | |
| GBGB9705041.3A GB9705041D0 (en) | 1997-03-12 | 1997-03-12 | Thiazole benzenesulfonamides as selective B3 agonists for the treatment of diabetes and obesity |
| PCT/US1998/001317 WO1998032753A1 (en) | 1997-01-28 | 1998-01-23 | THIAZOLE BENZENESULFONAMIDES AS β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG103686A true BG103686A (bg) | 2000-06-30 |
Family
ID=26311166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG103686A BG103686A (bg) | 1997-01-28 | 1999-08-24 | Тиазолови бензенсулфонамиди като бета3 агонисти за лечението на диабет и затлъстяване |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0968209A1 (zh) |
| JP (1) | JP2001509166A (zh) |
| KR (1) | KR20000070568A (zh) |
| CN (1) | CN1251099A (zh) |
| AR (1) | AR011092A1 (zh) |
| AU (1) | AU728812B2 (zh) |
| BG (1) | BG103686A (zh) |
| BR (1) | BR9807096A (zh) |
| CA (1) | CA2278739A1 (zh) |
| EA (1) | EA199900692A1 (zh) |
| EE (1) | EE9900328A (zh) |
| HR (1) | HRP980044A2 (zh) |
| HU (1) | HUP0002053A3 (zh) |
| ID (1) | ID22273A (zh) |
| IL (1) | IL131130A0 (zh) |
| IS (1) | IS5131A (zh) |
| NO (1) | NO993646L (zh) |
| PE (1) | PE52299A1 (zh) |
| PL (1) | PL334833A1 (zh) |
| SK (1) | SK100099A3 (zh) |
| TR (1) | TR199902442T2 (zh) |
| WO (1) | WO1998032753A1 (zh) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19824175A1 (de) * | 1998-05-29 | 1999-12-02 | Novartis Ag | Amino-azol-Verbindungen |
| DE122008000018I1 (de) | 2000-01-21 | 2008-08-14 | Novartis Pharma Ag | Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica |
| AU2710301A (en) * | 2000-01-28 | 2001-08-07 | Asahi Kasei Kabushiki Kaisha | Novel remedies with the use of beta3 agonist |
| PT1138685E (pt) | 2000-03-31 | 2004-08-31 | Pfizer Prod Inc | Processo para a preparacao de piridinas substituidas |
| SK632003A3 (en) * | 2000-07-13 | 2003-06-03 | Lilly Co Eli | Beta3 adrenergic agonists |
| US6498170B2 (en) | 2000-07-17 | 2002-12-24 | Wyeth | Cyclamine sulfonamides as β-3 adrenergic receptor agonists |
| US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
| US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
| US6410734B1 (en) | 2000-07-17 | 2002-06-25 | Wyeth | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists |
| US6369232B1 (en) * | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
| WO2002038544A2 (en) | 2000-11-10 | 2002-05-16 | Eli Lilly And Company | 3-substituted oxindole beta 3 agonists |
| EP1348706B1 (en) * | 2000-12-08 | 2009-08-19 | Takeda Pharmaceutical Company Limited | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof |
| AR035605A1 (es) | 2000-12-11 | 2004-06-16 | Bayer Corp | Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores |
| AR035858A1 (es) | 2001-04-23 | 2004-07-21 | Bayer Corp | Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3 |
| ATE316088T1 (de) * | 2001-06-22 | 2006-02-15 | Merck & Co Inc | Tyrosin-kinase inhibitoren |
| DE60211199T2 (de) | 2001-08-14 | 2007-02-01 | Eli Lilly And Co., Indianapolis | 3-substituierte oxindol-beta-3-agonisten |
| WO2003016307A1 (en) | 2001-08-14 | 2003-02-27 | Eli Lilly And Company | β3 ADRENERGIC AGONISTS |
| MXPA04002931A (es) * | 2001-10-12 | 2005-04-11 | Bayer Pharmaceuticals Corp | Heterociclos que contienen nitrogeno de 5 miembros sustituidos con fenilo para el tratamiento de la obesidad. |
| ES2242890T3 (es) | 2001-11-20 | 2005-11-16 | Eli Lilly And Company | Agonistas beta 3 de oxindol 3-sustituido. |
| JP2005518357A (ja) | 2001-11-20 | 2005-06-23 | イーライ・リリー・アンド・カンパニー | ベータ３アドレナリンアゴニスト |
| WO2003059348A1 (en) | 2002-01-11 | 2003-07-24 | Eli Lilly And Company | 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as beta3 agonists |
| US6872724B2 (en) | 2002-07-24 | 2005-03-29 | Merck & Co., Inc. | Polymorphs with tyrosine kinase activity |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
| WO2006132196A1 (ja) * | 2005-06-08 | 2006-12-14 | Asahi Kasei Pharma Corporation | β３作動薬を含有する新規な医薬 |
| CA2622608C (en) | 2005-09-14 | 2014-08-19 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
| AU2006297443B2 (en) | 2005-09-29 | 2010-08-12 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| WO2007044296A2 (en) * | 2005-10-04 | 2007-04-19 | Merck & Co., Inc. | Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence |
| EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
| EA020466B1 (ru) | 2007-06-04 | 2014-11-28 | Синерджи Фармасьютикалз Инк. | Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
| CN102834393B (zh) | 2010-02-03 | 2015-07-22 | 武田药品工业株式会社 | 细胞凋亡信号调节激酶1抑制剂 |
| AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| EP3243385B1 (en) | 2011-02-25 | 2021-01-13 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗糖尿病性三環式化合物 |
| ES2394349B1 (es) | 2012-08-29 | 2013-11-04 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar |
| US9784726B2 (en) | 2013-01-08 | 2017-10-10 | Atrogi Ab | Screening method, a kit, a method of treatment and a compound for use in a method of treatment |
| CN104994848A (zh) | 2013-02-22 | 2015-10-21 | 默沙东公司 | 抗糖尿病二环化合物 |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| PT3004138T (pt) | 2013-06-05 | 2024-06-18 | Bausch Health Ireland Ltd | Agonistas ultrapuros de guanilato ciclase c, método de produção e utilização dos mesmos |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| GB201714740D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714736D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0091749A3 (en) * | 1982-04-08 | 1984-12-05 | Beecham Group Plc | Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them |
| US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| IL113410A (en) * | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
-
1998
- 1998-01-23 BR BR9807096-7A patent/BR9807096A/pt not_active IP Right Cessation
- 1998-01-23 CN CN98803585A patent/CN1251099A/zh active Pending
- 1998-01-23 WO PCT/US1998/001317 patent/WO1998032753A1/en not_active Application Discontinuation
- 1998-01-23 JP JP53214898A patent/JP2001509166A/ja active Pending
- 1998-01-23 KR KR1019997006814A patent/KR20000070568A/ko not_active Application Discontinuation
- 1998-01-23 CA CA002278739A patent/CA2278739A1/en not_active Abandoned
- 1998-01-23 ID IDW990755A patent/ID22273A/id unknown
- 1998-01-23 AU AU60384/98A patent/AU728812B2/en not_active Ceased
- 1998-01-23 HU HU0002053A patent/HUP0002053A3/hu unknown
- 1998-01-23 EP EP98903677A patent/EP0968209A1/en not_active Withdrawn
- 1998-01-23 TR TR1999/02442T patent/TR199902442T2/xx unknown
- 1998-01-23 EA EA199900692A patent/EA199900692A1/ru unknown
- 1998-01-23 SK SK1000-99A patent/SK100099A3/sk unknown
- 1998-01-23 EE EEP199900328A patent/EE9900328A/xx unknown
- 1998-01-23 PL PL98334833A patent/PL334833A1/xx unknown
- 1998-01-23 IL IL13113098A patent/IL131130A0/xx unknown
- 1998-01-27 AR ARP980100357A patent/AR011092A1/es unknown
- 1998-01-28 PE PE1998000064A patent/PE52299A1/es not_active Application Discontinuation
- 1998-01-28 HR HR9705041.3A patent/HRP980044A2/hr not_active Application Discontinuation
-
1999
- 1999-07-23 IS IS5131A patent/IS5131A/is unknown
- 1999-07-27 NO NO993646A patent/NO993646L/no not_active Application Discontinuation
- 1999-08-24 BG BG103686A patent/BG103686A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20000070568A (ko) | 2000-11-25 |
| JP2001509166A (ja) | 2001-07-10 |
| IL131130A0 (en) | 2001-01-28 |
| SK100099A3 (en) | 2000-05-16 |
| ID22273A (id) | 1999-09-23 |
| HUP0002053A3 (en) | 2001-09-28 |
| TR199902442T2 (xx) | 2000-07-21 |
| BR9807096A (pt) | 2000-04-18 |
| AR011092A1 (es) | 2000-08-02 |
| EP0968209A1 (en) | 2000-01-05 |
| PL334833A1 (en) | 2000-03-27 |
| AU6038498A (en) | 1998-08-18 |
| PE52299A1 (es) | 1999-05-26 |
| AU728812B2 (en) | 2001-01-18 |
| NO993646L (no) | 1999-09-27 |
| HUP0002053A2 (hu) | 2001-08-28 |
| HRP980044A2 (en) | 1998-10-31 |
| CN1251099A (zh) | 2000-04-19 |
| CA2278739A1 (en) | 1998-07-30 |
| EA199900692A1 (ru) | 2000-02-28 |
| IS5131A (is) | 1999-07-23 |
| NO993646D0 (no) | 1999-07-27 |
| WO1998032753A1 (en) | 1998-07-30 |
| EE9900328A (et) | 2000-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG103686A (bg) | Тиазолови бензенсулфонамиди като бета3 агонисти за лечението на диабет и затлъстяване | |
| AU712057B2 (en) | Oxadiazole benzenesulfonamides as selective beta3 agonists for the treatment of diabetes and obesity | |
| JP3149186B2 (ja) | 糖尿病および肥満の治療のための選択的β▲下３▼作用物質としての置換スルホンアミド | |
| US5451677A (en) | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity | |
| US6011048A (en) | Thiazole benzenesulfonamides as β3 agonists for treatment of diabetes and obesity | |
| AU717699B2 (en) | Chemical compounds | |
| US6291491B1 (en) | Amide derivatives as β 3 agonists | |
| US5705515A (en) | Substituted sulfonamides as selective β-3 agonists for the treatment of diabetes and obesity | |
| US5541197A (en) | Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity | |
| AU4689500A (en) | Di-aryl acid derivatives as ppar receptor ligands | |
| JP2006516254A (ja) | Ｐｐａｒモジュレータとしての縮合ヘテロ環誘導体 | |
| US20140094456A1 (en) | Anti-fibrotic pyridinones | |
| JP2000515133A (ja) | 血糖降下性および脂質低下性の化合物 | |
| JP4986927B2 (ja) | 医薬 | |
| US6034106A (en) | Oxadiazole benzenesulfonamides as selective β3 Agonist for the treatment of Diabetes and Obesity | |
| WO2021127301A1 (en) | 4-phenyl-n-(phenyl)thiazol-2-amine derivatives and related compounds as aryl hydrocarbon receptor (ahr) agonists for the treatment of e.g. angiogenesis implicated or inflammatory disorders | |
| CZ268199A3 (cs) | Thiazolbenzensulfonamidy a farmaceutický prostředek | |
| MXPA99007032A (en) | THIAZOLE BENZENESULFONAMIDES AS&bgr;3 | |
| GB2356196A (en) | Guanidine and ethylenediamine derivatives as beta 3 agonists | |
| Fisher et al. | Substituted Sulfonamides as Selective β3 Agonists for the Treatment of Diabetes and Obesity | |
| JPH1135534A (ja) | フェノキシ酢酸誘導体 |